ReportWire

Tag: RHHBY

  • Roche's Cancer Injection Tecentriq SC Gets European Commission Approval

    Roche's Cancer Injection Tecentriq SC Gets European Commission Approval

    [ad_1]

    By Andrea Figueras

    Roche said that the European Commission approved Tecentriq SC, a cancer immunotherapy subcutaneous injection for multiple cancer types.
    

    The Swiss pharmaceutical company said Tuesday that it has been granted marketing authorisation for Tecentriq SC, which reduces treatment time by approximately 80% compared with standard IV infusion.
    

    

    The subcutaneous injections take between four and eight minutes, while until now the treatment had been given directly into patients’ veins by IV infusion, which takes approximately 30-60 minutes.
    

    Last year, more than 38,000 people in the EU received Tecentriq to treat different types of lung, liver, bladder and breast cancer, Roche said.
    

    The company is also working closely with several providers in Europe to include Tecentriq SC in cancer homecare initiatives where possible.
    

    The injections can also be administered by a healthcare professional outside of the hospital, in a community care setting or at a patient’s home, depending on national regulations and health systems.
    

    Write to Andrea Figueras at andrea.figueras@wsj.com
    

    

    

    [ad_2]
    

    Source link 
    

    
			
    
		
    
		
	
  • 
		
		
    
			
    Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study
    
			
    Roche's Inavolisib Breast Cancer Drug Shows Promise in Late-Stage Study
    
			
     [ad_1]
    

    

    By Mauro Orru
    

    Roche Holding said its investigational treatment, inavolisib, showed promise in a late-stage study to treat patients with breast cancer.
    

    The Swiss pharmaceutical company said Tuesday that the phase 3 study met its primary endpoint of progression-free survival, showing that inavolisib, in combination with palbociclib and fulvestrant, delivered a statistically significant and clinically meaningful improvement compared to palbociclib and fulvestrant alone.
    

    

    While Roche acknowledged that overall survival data were immature at this stage, it said it had observed a clear positive trend. The inavolisib combination was well tolerated.
    

    The group said inavolisib is an investigational, oral targeted treatment with potential to provide durable disease control.
    

    Write to Mauro Orru at mauro.orru@wsj.com
    

    

    

    [ad_2]
    

    Source link 
    

    
			
    
		
    
		
	
  • 
		
		
    
			
    Roche Lung Cancer Drug Shows Promise in Phase 3 Trial
    
			
    Roche Lung Cancer Drug Shows Promise in Phase 3 Trial
    
			
     [ad_1]
    

    

    By David Sachs
    

    Roche said Friday that its Alecensa drug demonstrated the ability to reduce recurrence of lung cancer for patients in the early stage of the disease.
    

    The Swiss pharmaceutical company said the results, from a Phase 3 study of 257 people which compared the treatment with platinum-based chemotherapy, met its primary goal of disease-free survival in people with early-stage non-small cell lung cancer. About half of people with this type of lung cancer experience a recurrence of the disease after surgery, Roche said.
    

    

    Roche said that it found no unexpected safety issues and will submit the data to global health authorities.
    

    Write to David Sachs at david.sachs@wsj.com
    

    

    

    [ad_2]
    

    Source link